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Interest  in  heterologous antilymphocyte serum  (ALS)  as  an immunosup- 
pressive agent dates from the studies of Wilhelm et al. (1), Interbitzin (2), and 
Waksman et al. (3). These authors showed that an antiserum raised in rabbits 
against guinea pig lymph node cells, when injected into the latter animal, de- 
pleted lymphoid structures, reduced the numbers of circulating lymphocytes, 
and depressed immune responses. Similar results were subsequently obtained 
in mice (4) and in rats (5). A new impetus was given to the subject by the report 
of Woodruff and Anderson (6)  that administration of ALS could prolong the 
survival of experimental homografts in rats. This has since been confirmed in 
mice (4),  dogs (7),  and man (8).  Particular interest is attached to reports (9, 
10)  that suppression of graft rejection could be achieved by doses of ALS in- 
sufficient to lower significantly the numbers of circulating lymphocytes, sug- 
gesting that ALS may act by a  nondestructive interference with the partici- 
pation of lymphocytes in immunological reactions. 
These reports raised the possibility that ALS may offer a new approach in 
the treatment of those human diseases in which immune responses play an es- 
sential pathogenic role. It was therefore decided to study the influence of ALS 
on adjuvant disease in the rat (11).  In this experimental model, a single intra- 
cutaneous injection of Freund's complete adjuvant results, 9-14 days later, in 
the appearance of a marked and prolonged polyarthritis, as well  as  other le- 
sions. The arthritis is generally regarded as a delayed type of hypersensitivity 
response to disseminated mycobacterial antigen (12),  and thus appeared  to be 
an appropriate model in which to study the action of ALS. 
This report  describes  the influence of rabbit anti-rat lymphocyte globulin 
(ALG) on adjuvant arthritis and other immune responses in the rat,  and it 
compares the efficacy of antisera raised separately against thymus and lymph 
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node  cells.  Rats  receiving ALG  developed  antibodies  against  rabbit  globulin, 
and  the  influence  of  such  circulating  antibodies  on  the  activity  of  ALG  was 
also studied.  Two preliminary reports on this work have appeared  (13,  14). 
Materials and Methods 
Preparation of Antilymphocyte Serum.--Peritoneal  lymph nodes,  spleens,  and  thymuses, 
excised from various strains of rats, were crushed with forceps in Hanks' solution, then filtered 
through glass-wool columns (15). The resulting cell suspension, of which over 95% resembled 
small lympbocytes, was centrifuged once, then resuspended in Hanks' solution, and injected 
intraperitoneally into white New Zealand rabbits weighing approximately 3 kg. Each rabbit 
received between 200  X  106 and  1200  X  106 cells on each occasion. Three injections were 
given during the 1st wk, and one at the end of the 2nd, 3rd, and 7th wk. The rabbits were 
bled 7 days after the last injection, and subsequently 7 days after each booster injection. In all, 
they were bled nine times. Sera were inactivated by heating to 56°C  for 30 min, then stored 
at -  20°C. 
Processing of Serum.--Initially,  individual sera  were  tested  by  injecting 2  ml of  heat- 
inactivated, but otherwise untreated, serum intraperitoneally into rats and by comparing the 
absolute lymphocyte count before and 4 hr after injection. A majority of sera so tested reduced 
the count from an initial value of about 12,000/mm  3 to less than 15% of this value after 4 hr. 
However, many of the injected rats suffered a  severe reaction with collapse, and subsequent 
blood smears and hematocrit examinations showed evidence of a  severe hemolytic anemia. 
This method of selecting sera was therefore given up in favor of the lymphocyte agglutination 
test described below. Using this procedure, sera were included only if they  agglutinated rat 
lymphocytes in a  dilution greater than 1/64. 
The pooled sera were absorbed twice with 1/4 volume of packed rat erythrocytes from 
which the "buffy coat" had been removed during three washings with normal saline solution. 
Each absorption involved incubation of the ceils and serum at 37°C with intermittent agitation 
for 1 hr. The red cells were removed by centrifugation either immediately or after standing at 
4°C overnight. 
A crude globulin preparation was obtained by precipitation with 50% saturated ammonium 
sulphate, followed by washing with a  400/0 saturated ammonium sulphate solution. The pre- 
cipitate was redissolved in normal saline, then dialyzed for 4 days against normal saline. Mter 
dialysis, the volume was made up  to  that of the original serum, and the concentration of 
globulin determined from the optical density at 280 m#. At this stage, control normal rabbit 
globulin, prepared by an identical process from normal rabbit serum (Microbiological Associ- 
ates, Bethesda, Md.), was adjusted in volume to give a  similar final globulin concentration 
(this varied from 6.3 to 9.2 mg/ml in the various batches). Finally, both preparations were 
sterilized by passage through 0.45 #  Millipore filters and stored sterile at  --20°C in  12 ml 
aliquots. 
Adjuvant  Injection.--Adjuvant  was  prepared  by  homogenizing dried,  heat-killed Myco- 
bacterium tuberculosis (H37  Ra,  Difco Laboratories, Inc.,  Detroit,  Mich.)  in heavy mineral 
oil (E. R. Squibb & Sons, New York, N.Y.) to give a suspension of 6 mg M. tuberculosis per 
milliliter. The suspension was autoclaved, and rats under light ether anesthesia received 0.I 
ml by intracutaneous injection into the base of the tail. 
Rats.--Adult female rats weighing between 165 g and 210 g were housed in individual sheet 
metal cages and received a diet of commercial food pellets and water ad lib. Both Lewis rats 
(Microbiological  Associates)  and  Sprague-Dawley  rats  (Simonsen  Laboratories,  Gilroy, 
Calif.) were found to develop arthritis consistently following adjuvant injection and, except as 
specified below, one or the other of these strains was used for each experiment. Samples of H.  L. F. CURREY  AND  MORRIS  ZIFF  187 
blood were obtained under ether anesthesia from the orbital sinuses or (for blood counts) from 
the tail. All globulin preparations were administered intraperitoneally. 
Ouantitation o/Arthritis.--From  the 9th day after adjuvant injection, all rats were examined 
regularly for arthritis. At each examination, the wrists, ankles, tarsi, and tail were graded 0-4 
depending on the degree of swelling and redness, and each of the smaller joints (metacarpo- 
phalangeal, metatarsophalangeal, and interphalangeal) 0-2. The total score for aU these joints 
was used as an index of the severity of polyarthritis on a particular occasion. 
Lymphocyte Agglutination.--Lymph  nodes or thymuses from rats killed by exsanguination 
were crushed in Hanks' solution, then filtered through glass-wool columns. Next the celis were 
washed  three  times  in  a  buffer  solution  containing  1.96  g  Na2HPO,  0.65  g  NaH2PO, 
3.0 g Na2EDTA, and 3.5 g NaC1 per liter. Before use, the ceils were resuspended in a sufficient 
volume of this solution to give a  concentration of 50 X  106 ceils per milliliter, and 1% de- 
complemented normal rabbit serum was added.  Cells stored overnight at 4°C proved satis- 
factory for use. During preparation, some celis formed clumps which could not be resuspended, 
hence the ceU concentration had to be adjusted immediately before use. An occasional batch of 
TABLE  I 
Agglutinating Properties of Crude  A ntilymphocyte Serum and Absorbed Antilymphocyte Globulin 
Antilymphocyte  preparation 
Unabsorbed serum 
Ammonium  sulphate precipitated globulins after 
absorption with rat erythrocytes 
Agglutination  titer 
Antilyrnphocyte  titer 
1/256 
1/256 
Antierythrocyte titer 
1/512 
1/S 
cells proved unsuitable for use because of a  tendency to adhere to the sides of the plastic ag- 
glutination trays, The agglutination test was performed using Microtiter equipment (Cooke 
Engineering Co., Alexandria, Va.). 0.05 ml of cell suspension was added to 0.05 ml serial dilu- 
tions of serum with EDTA buffer in disposable plastic "U" plates. After 4 hr at room tempera- 
ture, the pattern of agglutination was read easily by eye. 
Hemagglutination Tests.--All hemagglutination tests were performed using Microtiter equip- 
ment with disposable U plates. 0.05 ml of a 1% suspension of the appropriate washed erythro- 
cytes (rat or sheep) was added to 0.05 ml of serum in serial dilutions. The results were read 
after 4 hr incubation at room temperature. 
Indirect hemagglutination tests for measuring rat anti-rabbit globulin and rabbit anti-rat 
globulin antibodies were performed by a  modification of the above procedure. Serum from a 
rat or a rabbit hyperimmunized to sheep erythrocytes was used to sensitize sheep erythrocytes 
by incubating the cells at 37°C for 30 rain with the appropriate serum diluted to  1/4 the basic 
agglutinating titer, after which the erythrocytes were washed three times. The sheep erythro- 
cytes, thus coated with a  subagglutinating dose of rabbit or  rat immune globulin, were then 
used in hemagglutination tests as above. These sera were tested also against unsensitized sheep 
cells,  with negative results, indicating the absence of  "heterophile" antibody.  Agglutination 
of  sensitized cells was  interpreted as  indicating the presence of  antibody  to  the  immune 
globulin (rat or  rabbit)  coating  the erythrocytes.  In  some instances, rat sera were  tested 
against rat erythrocytes sensitized with  a  subaggiutinating dose  of  an  appropriate  rabbit 
antiserum. 188  HETEROLOGOUS ANTILYMPHOCYTE SERUM 
Cotricosterone Determinations.--These  were  performed  by the  fluorometric  technique  of 
Guillemin et al. (16) using 0.2 ml of serum. Blood samples were drawn between 10 a.m. and 12 
noon. 
Urinalysis.--Rats  receiving intraperitoneal injections  almost invaraibly passed  at least a 
few drops of urine at the time of injection. Advantage was taken of this to test the urine with 
Labstix (Ames Co., Inc., Elkhart, Ind.) as a simple screening test for abnormal quantities of 
protein,  glucose,  and  blood. 
Immunofluorescence.--Goat anti-rabbit globulin was labeled with fluorescein isothiocyanate 
by the method of Spendlove (17). 
RESULTS 
In  Vitro Properties of ALG.--Table I  shows the results obtained with a typ- 
ical  batch  of rabbit  antilymphocyte  serum.  The  pooled  serum,  before  proc- 
essing, agglutinated rat lymphocytes in a  titer of 1/256 and rat erythrocytes in 
a  titer of 1/512.  Absorption twice with  1/4 volume of packed rat erythrocytes 
TABLE II 
Changes in the Absolute Lymphocyte Count in Rats Injected Intraperitoneally with 
Antilymphocyte Globulin or Normal Rabbit Globulin 
Prepa- 
ration 
injected* 
ALG 
(4 rats) 
NRG 
(4 rats) 
Absolute lymphocyte count (mean and range) X  lO-*/mmS 
Initial value 
10.5 
(9.7-12.8) 
8.5 
(7.5-9.1) 
1 hr 
11.6 
(9.3-12.8) 
11.5 
(9.3-13.1) 
2 hr 
4.4 
(2.4-7.3) 
10.8 
(8.8-12.7) 
3 hr 
3.3 
(0.8-7.7) 
9.4 
(6.2-11.4) 
4 hr 
2.5 
(1.9-3.3) 
5.7 
(4.7-6.4) 
24 hr 
6.5 
(1.9-11.4) 
10.9 
(8.4-13.0) 
* 2 ml, intraperitoneally. 
and ammonium sulphate  fractionation  reduced  the titer  of hemagglutinins  to 
1/8  without  affecting the  ant[lymphocyte  titer.  The  titers  of individual  ani- 
mals remained fairly constant through successive bleedings. 
An indirect  hemagglutination  technique  utilizing  sheep cells sensitized  with 
rat  antibody  was used  to test for the  presence  of antibodies  to  rat  globulin. 
Sera from early bleedings gave low titers  (0-1/16),  while in later bleedings the 
titers  rose to between  1/64  and  1/128.  However,  processing  of the  serum,  as 
described,  appeared  to remove these  antibodies,  for all batches  of ALG gave 
negative results. ALG also gave negative results in the standard sensitized sheep 
cell  agglutination  test  and  latex  fixation  text  (RA,  Hyland Laboratories,  Los 
Angeles,  Calif.) for rheumatoid factors. 
Response to Injection oJ ALG.--Table II shows  the  changes  in the absolute 
lymphocyte count following a  single  2 rnl injection  of ALG,  compared with  a 
similar injection of normal rabbit globulin  (NRG). 2 hr after injection of ALG, H.  L.  1¢.  CUP.R.EY AND  MORRIS  Z[FF  189 
the lymphocyte count was falling, and some effect was stiU apparent at 24 hr. 
By contrast, NRG produced only a modest depression at 4 hr. Daily injections 
of 1 ml of ALG for 3 wk maintained the lymphocyte count at approximately 
3,500/mm 3. Rats so treated showed no evidence of hemolytic anemia or other 
toxic effect, and maintained normal hematocrit values. 
Effect of ALG on Adjuvant Arthritis.--Fig.  1 shows the influence of a 21 day 
course of ALG on the progress of adjuvant arthritis in the rat. Treated animals 
received 2 ml of ALG on the day before adjuvant administration, followed by 
1 ml daily thereafter. Each point indicates the mean joint score in a group of 
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FIG. 1. Suppression of adjuvant arthritis by a 3 wk course of ALG. Variation in mean joint 
score in three groups of 10 rats each. 
10 rats on a particular day. All animals in the control groups, which received 
either no treatment or NRG, developed either moderate or severe polyarthritis 
beginning on the 9th to 12th day, increasing rapidly in severity up to the 15th 
day.  Gross  changes were still  present  when  the  experiment ended at  8 wk. 
By contrast, rats treated with ALG received considerable protection, showing 
either mild arthritis or none at all. After stopping treatment, there was no evi- 
dence of the "escape" which has been described after corticosteroid suppres- 
sion (18). 
Clinically, the animals that received ALG appeared healthier and were more 
active. Fig. 2 shows that they were spared the weight loss (which averaged 17 
g) and the fall in hematocrit (which averaged 8 %) experienced by the other two 
groups. The absolute lymphocyte counts are also shown.  Compared with the 
lymphocytosis seen in control animals, the ALG-treated animals receiving ad- 
juvant  developed a  modest lymphopenia. There was,  however, some escape 190  H]ETEROLOGOUS  ANTILYM~HOCYTE  SER~ 
from this lymphopenia in  comparison with animals given the same course of 
ALG without the adjuvant injection. 
Ral Anti-Rabbit Globulin Anlibodies.--Sera obtained from five rats in each 
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Fic. 2. Mean values of body weight, hematocrit, and peripheral lymphocyte count in three 
groups of rats before and after adjuvant injection. 10 rats in each group. (Same experiment as 
Fig. 1). Note that ALG-treated rats were spared the weight loss and anemia seen in controls. 
group on day 27,  1 wk after stopping globulin treatment,  were examined for 
the presence of antibodies to rabbit globulin. The results of an indirect hemag- 
glutination  test using  sheep  erythrocytes  sensitized  with  a  subagglutinating 
titer of rabbit amboceptor are shown in Table III. Both  the ALG- and NRG- H.  L.  F.  CURREY  AND  MORRIS  ZIFF  191 
treated  animals had high  titers  of anti-globulin antibodies,  the  titers  of the 
ALG-treated group being, if anything, slightly greater. Titers of earlier sera ob- 
tained on day 14 were about three dilutions lower in these two groups. 
Rat Serum Corticosterone Levels.--It was felt necessary to exclude the possi- 
bility that ALG suppressed adjuvant arthritis through an adrenocortical mech- 
anism. Serum corticosterone levels were therefore determined (16) on serum ob- 
tained from five rats in each group on day 14, at a time when the arthritis was 
TABLE  III 
Titer of Rat Antibodies to Rabbit Immunoglobulin I Wk after Stopping  Globulin Treatment 
Using a Sensitized Sheep Cdl Hemagglutination Test 
Treatment 
None 
NRG 
ALG 
No. of rats 
<t/4  ]]  1/512 
5 
4 
No. of rats showing titers of 
1/1024  1/2048  1/4096 
3  [  2 
TABLE  IV 
Serum Corticosterone Lords 14 Days after Injection of Adjuvant 
Treatment  No. of rats  Mean (and range) serum cortlcosterone* 
None 
NRG 
ALG 
#g/lO0 ml 
15.2 (10-27) 
8.6(5-16) 
9.6 (5-22) 
* Normal values under completely basal conditions are from 6 to  15/zg/100  ml.  (16). 
Stress involved in the ether anesthesia used to bleed these rats might account for the some- 
what higher values in some animals. 
increasing in the control groups and the globulin preparations were still being 
administered. Table IV shows the results. The distribution of serum levels in- 
dicates  no  adrenocortical  overactivity in  the  group  of  animals  treated  with 
ALG. 
Effect of Varying the Timing and Dosage of ALG.--Fig. 3 shows the influence 
of various ALG  treatment  regimens  on  the  course  of  adjuvant  arthritis.  A 
single injection of 2 ml, given on the day before adjuvant injection, had little 
if any effect, while three daily injections of 2 rnl, bracketing the time of adjuvant 
injection,  produced  almost as efficient suppression  as the full 21  day course. 
Later administration of ALG for periods of 1 wk produced progressively less 192  ttETEROLOGOUS  ANTILYMPttOCYTE  SERUM 
suppression. However, there appeared to be some depression in the curve of the 
mean joint score, even in the groups started on ALG either late in the incubation 
period or actually after the onset of arthritis. The shape of these curves suggests 
that ALG given late produced mild suppression limited strictly to the time of 
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Fio. 3. The influence of timing and dosage of ALG on the suppression of adjuvant arthritis. 
Progressive mean joint score in each group of rats is plotted by a symbol which also indicates 
(above) the course of treatment received by that group. Note slight suppression in the group 
given ALG after the onset of arthrltis. Rats were challenged with sheep erythrocytes on day 
15 and bled 1 wk later. The distribution of hemagglutination  fiters among the various groups 
is also shown  (top right). 
administration--a pattern suggestive of antiinflammatory activity rather than 
immune suppression. 
Effect of ALG on the Primary Antibody Response  to Sheep Red Blood  Cells.- 
To assess immunological competence in the animals used in these experiments, 
five rats in each group were injected intraperitoneally with 1 ml of a  10 %  sus- H.  L.  F.  CUR.REY AND  MORRIS  ZIFF  193 
pension of washed sheep erythrocytes on day 15. They were bled 1 wk later 
(day 22),  and the distribution of hemagglutination  titers among the various 
groups is given in Fig. 3. The brisk antibody response seen in the two control 
groups was completely prevented by ALG treatment for 3 wk. Shorter courses 
produced partial suppression.  The numbers concerned are too few to draw firm 
conclusions,  although the pattern suggests that ALG suppressed this primary 
TABLE V 
Agglutinating Properties of "Ant#ymp~cyte"  and "Antitkymocyte" Globulin Preparations 
Agglutination titer for cells obtained from* 
Antiserum preparation 
Lymph nodes  Thymus 
AntNympttocyte globulin  1/64  1/128 
Antitkymoeyte globulin  1/64  1/128 
* Repeated testing of different batches of cells from these sources revealed no consistent 
difference in sensitivity to agglutination. The one-tube difference shown here is not significant. 
Anti/lymph node cell globulin 
or 
Anti/thymus cell globulin 
or 
Normal  rabbit globulin 
(2ml  i.p. daily x5days) 
t 
Adjuvant 
Injection  t  tt 
SRBC  PPD  Antibody 
Skin  Titer 
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FIO. 4. Design of experiment to compare the in vivo activity of antisera prepared against 
thymus cells and lymph node cells. 10 rats in each group. Challenge with sheep erythrocytes 
was intentionally delayed to avoid complete suppression of antibody response. 
antibody response  most efficiently when given shortly before antigen adminis- 
tration. 
Comparison of Antisera to Lymph Node and Thymus Cells.--Two groups of 
rabbits were used to produce separate antisera against lymphoid cells from rat 
lymph nodes and rat thymuses. The immunizing  program and method of proc- 
essing the globulin were identical with that used in the preparation of ALG, ex- 
cept that  the different  groups of rabbits were injected only with the appro- 15 
10 
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priate type of cell. Table V shows the result of an agglutination test comparing 
the properties of these two globulin preparations. The two were equally potent, 
and showed no differences in specificity for the two types of cells used in immu- 
nization.  Differences in specificity were also looked for by immunofluorescent 
methods. Sections of rat lymph node and thymus, after incubation with one or 
the other globulin preparation, were exposed to fluoresceinated goat anti-rabbit 
L:  Anti-lymph  node  cell  globulin 
T:  Anti-thymus  cell  globulin 
50  N:  Normal  rabbit  globulin 
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Fro. 5. Comparison of in vivo activity of antisera prepared against thymus cells and lymph 
node cells (results of experiment illustrated in Fig. 4). Lymphocyte counts were determined 3 
hr after the fourth injection of globulin. Joint scores represent  the maximum score achieved 
by each rat. The antibody response to a challenge with sheep erythrocytes and the result of a 
skin test using PPD are also shown. Note that there is no difference in activity between anti- 
sera to thymus and lymph node cells, and that the PPD skin reaction was almost unaffected 
despite marked  suppression of arthritis.  Control  rats,  not given adjuvant,  had completely 
negative skin tests to PPD. 
globulin antibody. There appeared to be equal  affinity of the two preparations 
for each type of tissue.  These results,  therefore, indicated no gross differences 
in specificity between the two antisera with regard to their affinity for cells ob- 
tained from the thymus or from lymph nodes. (They were also taken to indicate 
that either type of cell  was suitable for use in lymphocyte agglutination tests. 
In practice,  the larger number of cells  obtainable from the thymus,  with less 
erythrocyte contamination, made this the more convenient source). H.  L.  F.  CURREY AND  MORRIS ZIFF  195 
The biological activity of the two globulin preparations in vivo was com- 
pared in the experiment shown in Fig. 4. Three groups of 10 rats were each 
given 2 ml of a  globulin preparation (antilympkocyte, antithymocyte, or NRG) 
daily for 5 days. 3 hr after the fourth injection (day 0), absolute lymphocyte 
counts were performed, and each animal was injected with adjuvant. 1 ml of a 
10 % suspension of sheep red blood ceils was injected on day 9, and blood was 
taken for a  hemagglutination test on day 16,  antigen challenge being inten- 
tionally delayed to  avoid complete suppression  of the response.  All animals 
were skin-tested,  with 0.1  ml  (5  #g)  of  "second strength" purified protein 
derivative (PPD, Merck Sharp  & Dohme, Rahway, N.J.) on day 14. 
I  Alum  I  Globulin 
pptd.  protein  i.p.  prep. i.p. 
2.8mg  2.8mg  2 ml 
NRG  NRG  ALG 
BSA  BSA  ALG 
NRG  NRG  NRG 
Nil  Nil  Nil 
t 
Adjuvant 
injection  t  tt 
SRBC  PPD  Antibody 
Skin  Titer 
Test 
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FIG. 6. Design of experiment to determine the influence on ALG activity of prior hyper 
immunization  with rabbit globulin. All rats given aim-precipitated rabbit globulin  had high 
titers of antibodies to rabbit globulin on day --3. 
Fig. 5 summarizes  the results.  Compared  to NRG, both  the active prepa- 
rations reduced the peripheral lymphocyte count and suppressed both adjuvant 
arthritis and the primary antibody response, and to an approximately equal 
extent. Both may have produced a slight reduction in the intensity of the skin 
reaction to PPD, but it is of interest that the reaction was still clearly positive 
compared to control rats not injected with adjuvant, even in those animals 
completely protected from arthritis. 
The Influence  of Circulating Anti-Rabbit Globulin Antibodies  on the Activity 
of ALG.--The experiments described above had shown that all rats receiving 
ALG developed precipitating antibodies to rabbit globulin in their serum. This 
raised the question of whether the presence  of such antibodies modified the 196  HETEROLOGOUS  ANTILYM~PHOCYTE  SERDM 
activity of ALG, or made its administration hazardous to the recipient. The 
experiment illustrated in Fig. 6  was designed to investigate these questions. 
The parameters used in the previous experiment were again examined in com- 
paring the activity of ALG in a  group of five rats hyperimmunized to normal 
rabbit globulin with its activity in animals hyperimmunized to an  unrelated 
antigen, bovine serum  albumin  (BSA).  Immunization was  achieved by two 
intraperitoneal injections of 2.8  mg of the appropriate  alum-precipitated an- 
A:  NRG ~  ALG 
15  30 
~L  B:  BSA  ~ALG 
•  C:  NRG ~  NRG 
•  D:  0  .-a....- 0 
10  20  •  20  •  •e 
..~ 
oo  a~• 
•  ~  •  •  • 
5  •  10  ~  ee  •  •  10 • ~  •  • 
•  •  5  •  '•O0  H  • 
4 
3  •  •0 
O0 
O  O  •  eo  <2  •  • 
A  B  C  D  A  B  C  D  A  B  C  D  A  B  C  D 
Absolute  Hemagglutinin  PPD 
Lymphocyte  Joint  Score  Titer  Skin  Reaction 
Count  (max)  (log 2  recip  titer)  at 24hr 
(xl0-3/mm3)  (mm  diam 
induration) 
FIO. 7. The influence of circulating antibodies to rabbit globulin on the activity of ALG 
(result of experiment illustrated in Fig. 6). Data presented as in Fig. 5. The use of (Lewis X 
BN) F1 hybrid rats in this experiment accounts for the somewhat lower joint scores. Note that 
ALG activity is at least as great in rats hyperimmune to rabbit globulin as in controls. There 
is a  tendency for NRG given to hyperimmune rats to have similar, but less marked, effects. 
tigen (19).  An indirect hemagglutination test on serum obtained on day -3, 
before giving the first ALG injection, showed all rats  pretreated with alum- 
precipitated rabbit  globulin to have antiglobulin titers of between 1/256 and 
1/1024.  Untreated  rats  gave negative  results.  As  illustrated,  one  group of 
controls received alum-precipitated  globulin followed by NRG,  another  re- 
ceived no globulin treatment. 
Fig. 7 shows the results. In both groups receiving ALG (groups A and B), 
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There was also a tendency for the primary antibody resPonse to sheep eryth- 
rocytes and the PPD skin reaction to be reduced. These effects were at least 
as great in the group hyperimmunized to globulin compared to the group pre- 
treated with BSA. The results  thus indicate no inhibition of ALG activity by 
the presence of circulating antiglobulin antibodies,  and they do not exclude the 
possibility of slight potentiation. It will be noted that there is a tendency for 
normal rabbit globulin given to hyperimmune rats (group C) to produce some- 
what similar, although less marked, effects. This appears  to be an exaggeration 
of a tendency, noted throughout these studies, for NRG, when given in larger 
doses, to interfere with immune responses and lower the absolute lymphocyte 
count. 
Urine Examincaion and Renal  Histology.--During the course of the experi- 
ment illustrated in Figs. 6 and 7, the urine of rats receiving globulin prepara- 
tions was, with few exceptions, tested on each occasion that globulin was ad- 
ministered. By the simple screening test used, none of the specimens contained 
abnormal concentrations of protein, blood, or glucose. Histological sections were 
obtained on day 25 from animals in group A (those immunized to rabbit glob- 
ulin, then given ALG). Sections were also obtained from four rats immunized 
to rabbit globulin then given NRG for 5 days (like group  C) and killed 6 hr 
after the last injecton. All sections  were stained with hematoxylin and eosin 
and with periodic acid-Schiff stain. None showed any abnormal changes in the 
basement membrane or elsewhere. 
DISCUSSION 
In the preparation of ALG, Freund's complete adjuvant was omitted from 
the immunizing program used,  lest its inclusion might confuse the interpre- 
tation of the influence of ALG upon adjuvant arthritis. This probably resulted 
in a less potent preparation than might otherwise  have been obtained. Also, 
the number of ceils used for immunization was relatively small compared to the 
massive doses which enabled lwasaki et al. (20) to produce in horses an anti- 
serum of very much greater agglutinating potency. The results  obtained in 
these experiments, therefore, probably reflect those to be expected from a rela- 
tively mild antilymphocyte treatment regimen, although the criteria for eval- 
uation of the potency of antilymphocyte  preparations are still uncertain. This 
decreased potency was apparent in the relatively modest lymphopenia resulting 
from single or repeated injections  of ALG. However,  some reduction in the 
numbers of circulating  lymphocytes did occur in all  animals that showed de- 
pressed immune responses. 
Adjuvant disease in the rat probably represents an immune response to a  dissemi- 
nated antigen present in M. tuberculosis (12). It provides a convenient experimental 
model for evaluating antiinflammatory and/or immunosuppressive drugs and,  in 
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same drugs in conditions such as rheumatoid arthritis (18, 21-24). Measured by this 
yardstick, ALG was observed to be a potent suppressive agent in doses which were not 
toxic to the rats. The efficient suppression obtained by a short course of ALG covering 
the time of adjuvant injection, and the absence of "escape" after stopping treatment, 
suggest that ALG interfered with the initiation of an immune reaction. However, when 
given later in the course of the disease, ALG produced slight suppression, apparent 
only during the period of administration, suggesting an antiinflammatory effect in this 
instance. Such combined immunosuppressive and antiinflammatory effects are known 
to occur with the use of antimetabolites such as 6-mercaptopurine (21). Another simi- 
larity between ALG and drugs like 6-mercaptopurine is their ability to suppress adju- 
vant arthritis without influencing the skin reaction to PPD  (Fig. 5)  suggesting that 
tuberculoprotein is not the responsible antigen in adjuvant arthritis (21). Evidence for 
an antiinflammatory action of ALG was in fact obtained by Morris et al. (25), who 
showed that an antilymphocyte preparation suppressed the inflammatory response to 
bacterial infection in guinea pigs. From the viewpoint of treating disease in man, ALG 
thus emerges as an alternative to the antimetabolite group of drugs for the treatment 
of the so-called autoimmune diseases. The advantage of ALG lies in its ability to pro- 
duce profound immune suppression without critical reduction of formed elements in 
the circulation or elsewhere. Against this, of course, the hazards of repeated injections 
of foreign protein must be weighed. 
Antilymphocyte  preparations have been shown to suppress a variety of other experi- 
mentally induced disorders, including allergic encephalomyelitis in the guinea pig (3), 
Coombs-positive hemolytic anemia in NZB mice (26),  lymphocyte choriomeningitis 
in the mouse (27), and graft-versus-host disease (28). However, ALG did not prevent 
the appearance of renal disease in (NZB x NZW) F1 mice (29). 
Gray et al. (30)  explored the possibility that the immunosuppressive and lympho- 
cytopenic effects of ALG might be mediated through adrenocortical stimulation. Al- 
though they considered this unlikely, the results of their experiments in mice were not 
conclusive. Attempts were made in the present experiments to exclude this possibility. 
Efforts to repeat these experiments in appropriately supplemented, adrenalectomized 
animals were unsuccessful both because of poor survival of adrenalectomized rats with 
adjuvant disease, and also because of undue susceptibility of these animals to the stress 
of ALG injections. However, the relatively normal serum corticosterone levels meas- 
ured in rats receiving ALG (Table IV) are interpreted as strong evidence against any 
significant contribution to the results by increased adrenal steroid secretion. 
ALG is produced against crude whole lymphocytes and would be expected to con- 
tain antibodies to a wide range of cellular antigens. Some of these antigens would be 
shared by many cells in the donor animals, while others might be specific for narrower 
cell lines. Iwasaki et al. (20)  found that absorption of ALS with either liver or kidney 
cells reduced the lymphocyte agglutinating titer by 90% although, like ourselves, they 
found no loss during absorption with red blood cells. In addition, Levey and Medawar 
(31)  have prouced antisera both to epidermal and  to L  cells which can prolong the 
survival of mouse homografts. These results suggest a  much  broader specificity for 
these preparations than is implied in the term "antilymphocyte." However, Nagaya 
and Sieker (5) and Kubista et al. (32) found differences in the biological activity of an 
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cells, suggesting that the latter might be more potent. In addition, Potworowski and 
Nairn (33) have detected an antigen present in subceUular fractions of thymocytes not 
shared by lymphocytes. 
It seemed important, therefore, to determine whether there were any significant 
differences between antisera raised separately against lymph node cells and against 
thymus  cells. In vivo biological differences between such  antisera might represent 
either differences in the relative strength of the preparations, i.e. the concentration of 
antibody, or differences in the pattern of specificity, i.e., varying activity against dif- 
ferent target cells. We were careful for this reason to use identical immunizing pro- 
grams in producing antisera against cells from these two sources. The globulin prepara- 
tions obtained from pools of such antisera had identical agglutinating titers for both 
lymph node and thymus cells (Table V). This we have taken to indicate that the two 
preparations were equipotent in a general sense, and that neither showed any greater 
affinity for one or the other cell type. The latter observation was confirmed by immuno- 
fluorescence testing. In vivo, both preparations reduced peripheral lymphocyte counts, 
suppressed adjuvant arthritis, and  inhibited primary antibody responses, all to an 
equal extent. Thus we have been able to detect no quantitative or qualitative differ- 
ences between these preparations. 
Levey and Medawar (31) found that, in rabbits immunized against mouse lympho- 
cytes, the initial bleeding produced the most potent antilymphocyte serum, and that 
longer courses of injections yielded less effective sera.  In the experiments described 
here, the rabbits were boosted and rebled a  total of nine times. Comparison of early 
and late bleedings showed no significant differences in lymphocyte agglutination titer, 
and immunosuppression was achieved with all batches of ALG, although the relative 
efficiency of early and late sera in this regard was not specifically  compared. Successive 
bleedings were found to have increasing titers of antibodies against rat immunoglobu- 
lin. Thus,  the specificity of ALG probably broadens with  continued immunization 
without increase in the specific antilymphocyte activity. 
Gray et al. (30)  found that rabbit anti-mouse lymphocyte serum  inhibited the ap- 
pearance of antibodies to rabbit immune globulir~ in recipient mice, and suggested that 
this might explain the long-term effectiveness of their preparation. Our experience in 
rats differs in that all animals given ALG developed precipitating antibodies to rabbit 
immunoglobulin, and the resulting fiters were at least as high in rats given ALG as in 
animals given a similar course of NRG. These antibodies might be expected to modify 
the biological activity of ALG, either by accelerating immune elimination, or by form- 
ing immune complexes with ALG which left the lymphocyte-binding sites intact. The 
former would be expected to decrease, and the latter, perhaps, to leave unchanged or 
even to increase "antilymphocyte" activity. In the present experiments, ALG, given to 
rats having high titers of circulating antibodies against rabbit immunoglobulin, pro- 
duced at least as much immunosuppression and lymphopenia as in animals not so pre- 
immunized. To what extent this represents a balance of effects is not dear. 
Circulating antibodies to globulin also represent a potential hazard to the recipient, 
if ALG is used therapeutically. A situation would arise in which there would be a risk, 
at least in theory, of anaphylactic shock, serum sickness, and renal damage. The extent 
to which information about this can be obtained from the results of experiments in rats 
is clearly limited. However, it is encouraging that none  of  the  rats  used  in  these 200  HETEROLOGOUS ANTILYM:PHOCYTE SERUM 
experiments showed any evidence of toxicity to ALG. There was no sign of collapse or 
other reactions following injections,  and treated rats did not become anemic. Repeated 
tests for proteinuria and hematuria were always negative and, even in the provocative 
situation where ALG was given to rats already hyperimmunized to rabbit globulin, no 
abnormality of renal histology was detected by light microscopy,  although the tissues 
were not examined  with the electron microscope.  During the course of these experi- 
ments, a few rats developed chronic respiratory infection, but this complication was no 
more frequent among the ALG-treated animals than among controls. 
The slight reduction in peripheral lymphocyte counts and the slight suppression  of 
immune responses noted when larger doses of NRG were given to control  animals re- 
main unexplained.  Both might represent a stress reaction. Alternatively,  the immune 
suppression  might be due to antigen  competition, or to the presence  of the a2-glyco- 
protein fraction of serum  globulin which Mowbray (34) has shown to interfere with 
allograft rejection.  In the case of adjuvant arthritis, Pearson and Wood  1 have shown 
that incorporation of an irrelevant protein such as ovalbumin into the adjuvant reduces 
the severity of the subsequent arthritis. Whatever the  explanation,  the implications 
about the necessity for adequate controls in experiments with antilymphocyte prepara- 
tions are obvious. 
The group of human diseases sometimes referred to as autoimmune includes 
a variety of conditions of unknown etiology in which immunological overactivity 
is prominent.  Current  concepts assign an essentially pathogenic role to such 
immune processses, and this provides the rationale for treatment with immuno- 
suppressive drugs such as azathioprine and cyclophosphamide. The usefulness of 
immunosuppressive agents in these conditions is not yet established, but across 
a wide therapeutic front the reports are at least encouraging (35). The studies 
reported here have shown that the known efficacy of ALG in suppressing allo- 
graft  rejection  also  extends  to  suppression  of  an  immunologically  induced 
disease in the rat by a relatively mild dosage regimen, and encourages the hope 
that it may prove an effective form of therepy in human disease. Only clinical 
experience will show whether the lack of toxicity seen in the rat extends to man. 
SUMMARY 
The effect d  antilymphocyte globulin  (ALG) on adjuvant arthritis, an im- 
munologically induced  disease  in  the  rat,  was  studied.  ALG was  prepared 
from the serum of rabbits immunized against rat lymphocytes. 
Adjuvant arthritis was induced in rats by a  single intracutaneous injection 
of Freund's complete adjuvant;  after 9 to 12 days, all control rats developed 
polyarthritis. Administration of antilymphocyte globulin about the time of ad- 
juvant injection produced marked inhibition of clinical disease. Some suppres- 
sion  was  apparent  even when  ALG was  started  after the  onset  of arthritis. 
Rats  receiving  ALG  remained  conspicuously  healthy  compared to  controls. 
Urinary findings and renal histology showed no evidence of nephritis. The re- 
sults  d  serum  corticosterone  determinations  made  it  unlikely  that  adrenal 
stimulation contributed to the actions of ALG. 
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Antilymphocyte  preparations  lowered  peripheral  lymphocyte  counts  and 
suppressed primary antibody responses to  sheep erythrocytes,  but had little 
effect on the skin reaction to PPD, even in rats protected from arthritis. 
All rats given  ALG developed antibodies  to rabbit globulin;  there was no 
evidence that ALG inhibited the  appearance of antibodies to itself, and prior 
hyperimmlm~zation of rats with rabbit globulin did not interfere with the bio- 
logical activity of ALG subsequently injected. 
Antisera produced separately against lymph node and thymus cells had iden- 
tical properties with regard to agglutination of lymphocytes and  thymus cells. 
Administered to rats, these preparations were equally potent in lowering lym- 
phocyte counts and suppressing both adjuvant arthritis and the primary anti- 
body response to sheep erythrocytes. 
It is concluded that ALG, as used in these experiments, is a potent immuno- 
suppressive agent without obvious toxic effects. 
We thank Dr. J. C. Porter for measuring the serum corticosterone levels, Dr. Stanley W. 
Strunk for examining the histological sections, and Dr. Hugo E. Jasin for helpful advice. 
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